SHR-1905
Phase 3- Indications
- Chronic rhinosinusitis with nasal polyps
Company intelligence / Profile preview
Guangdong Hengrui Pharmaceutical
Guangzhou, Guangdong, Chinaavancesenfibrosispulmonar.com ↗
- Ownership
- Private
- Employees
- ~25000
- Development stage
- Phase 3
01
Overview
Hengrui has over nineteen new molecular entity drugs commercialized in China with four additional innovative drugs on the market. The company conducts approximately four hundred clinical trials for more than ninety innovative drug candidates globally. Recent approvals include monoclonal antibodies for hypercholesterolemia and late-stage assets for autoimmune conditions. The group’s R&D engine covers a broad spectrum of modalities with robust international expansion efforts underway.
- Therapeutic areas
- PulmonologyOncologyMetabolic DisordersImmunologyDermatologyCardiovascularNeurologyInfectious Diseases
- Modalities
- Monoclonal antibodyBiological productsSmall moleculeFab fragmentFusion protein
- Industry
- Pharma
02
Drug pipeline
1 asset03
Partnerships
Engages in collaborations with multinational pharmaceutical firms for co-development/licensing/international trialsKnown to have outlicensing deals internationally
Beyond the preview
Go deeper on Guangdong Hengrui Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangdong Hengrui Pharmaceutical.